Immunosuppression Therapy

Patients with immune-mediated inflammatory disease undergoing immunosuppressive therapy gain a “significant immunological boost” following SARS-CoV-2 infection, according to data published in The Lancet Rheumatology.

Pediatric patients with IgA vasculitis nephritis and nephrotic-range proteinuria achieved remission after 12 months of mycophenolate mofetil-based immunosuppression treatment, according to data published in Kidney Medicine.

Further research is needed to ‘deconvolute’ the risk of poor COVID-19 vaccine response in patients treated with immunomodulatory drugs, according to a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.

Nearly 90% of adults with chronic inflammatory disease who were taking immunosuppressive medication had an antibody response after receiving an mRNA vaccine for SARS-CoV-2, according to findings in Annals of Internal Medicine.

Researchers who compared kidney transplant recipients randomized to withdrawal or continue corticosteroids 7 days after the procedure found no difference in allograft survival at 15 years.

President Donald J. Trump today approved a legislative package that includes lifetime coverage of immunosuppressants for kidney transplant recipients.

The U.S. Senate voted in favor of legislation that extends Medicare coverage of immunosuppressants to all kidney transplant recipients, regardless of age, and ensures these medications are covered for life.

Legislation that offers lifetime immunosuppressive drug coverage for Medicare patients who receive a kidney transplant regardless of age has passed the U.S. House of Representatives.

A recent analysis by the Congressional Budget Office estimates Medicare could save $400 million in the course of 10 years if lifetime immunosuppressive drug coverage were offered to Medicare patients with a kidney transplant.